publication date: Dec. 19, 2010

In this issue: 

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

Capitol Hill: With money tight, support for 2015 goal is symbolic.

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

NCI selects nanotech centers for funding.

Download (PDF 490KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.